The DOI matches its Crossref record.
Treatment of Narcolepsy with γ-Hydroxybutyrate. A Review of Clinical and Sleep Laboratory Findings
Abstract
Previous studies on the effects of gamma-hydroxybutyrate (GHB) on the sleep and clinical response of patients with narcolepsy are reviewed. New information on 48 patients treated with GHB for as long as 9 years is presented. These studies indicate that 2.25 to 3.00 g of GHB, taken in conjunction with a low dose of a stimulant during the day, rapidly alleviate the symptoms of narcolepsy in most patients. Tolerance does not develop to this treatment regimen; neither have any patients discontinued the treatment because of side effects. In poor responders, daytime drowsiness and not cataplexy has been the most common residual symptom. Sleep studies reveal that GHB induces REM followed by slow wave sleep. Although total sleep time at night may be unchanged, sleep is less fragmented. GHB appears to be effective because it can induce the symptoms of narcolepsy and contain them at night. It is noteworthy, therefore, that the central biochemical changes induced by GHB also appear comparable to those found naturally in narcolepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Synthesis, structure and properties of polyhydroxyalkanoates: biological polyesters
Sudesh, K., Abe, H., & Doi, Y. (2000) · Progress in Polymer Science · doi:10.1016/s0079-6700(00)00035-6 · Cited by 2,254
GABA, ?-hydroxybutyric acid, and neurological disease
Ting Wong, C. G., Bottiglieri, T., & Snead, O. C. (2003) · Annals of Neurology · doi:10.1002/ana.10696 · Cited by 488
THE γ-HYDROXYBUTYRATE SIGNALLING SYSTEM IN BRAIN: ORGANIZATION AND FUNCTIONAL IMPLICATIONS
MAITRE, M. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00064-0 · Cited by 453
PHARMACOLOGICAL ASPECTS OF HUMAN AND CANINE NARCOLEPSY
NISHINO, S., & MIGNOT, E. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00070-6 · Cited by 449
Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Vijay, N., & Morris, M. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990462 · Cited by 408
Narcolepsy:Clinical Features, New Pathophysiologic Insights, and Future Perspectives
Overeem, S., Mignot, E., GertvanDijk, J., & Lammers, G. J. (2001) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-200103000-00002 · Cited by 333
GHB: a new and novel drug of abuse
Nicholson, K. L., & Balster, R. L. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00191-5 · Cited by 320
What Keeps Us Awake: the Neuropharmacology of Stimulants and Wakefulness Promoting Medications
Boutrel, B., & Koob, G. F. (2004) · Sleep · doi:10.1093/sleep/27.6.1181 · Cited by 307
Terraneo, A., Leggio, L., Saladini, M., Ermani, M., Bonci, A., & Gallimberti, L. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.11.011 · Cited by 281
“…(Reimherr et al., 1998) and pramipexole (Corrigan et al., 2000; Mah et al., 2011) may improve depressive symptoms, oxazepam (Ansseau et al., 1990) may relief anxiety-related symptoms and triazolam (Pakes et al., 1981), and gamma hydroxybutyrate (Mamelak et al., 1985) may improve sleep problems.”
BackgroundGamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence
Galloway, G. P., Frederick, S. L., Staggers, F. E., Gonzales, M., Stalcup, S. A., & Smith, D. E. (1997) · Addiction · doi:10.1046/j.1360-0443.1997.921899.x · Cited by 277
GAMMA-HYDROXYBUTYRIC ACID FOR TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME
Gallimberti, L., Gentile, N., Cibin, M., Fadda, F., Canton, G., Ferri, M., Ferrara, S. D., & Gessa, G. L. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90842-8 · Cited by 266
The neurobiology, diagnosis, and treatment of narcolepsy
Scammell, T. E. (2003) · Annals of Neurology · doi:10.1002/ana.10444 · Cited by 261
Excessive daytime sleepiness: A challenge for the practising neurologist
Guilleminault, C. (2001) · Brain · doi:10.1093/brain/124.8.1482 · Cited by 260
EFNS guidelines on management of narcolepsy
Billiard, M., Bassetti, C., Dauvilliers, Y., Dolenc‐Groselj, L., Lammers, G. J., Mayer, G., Pollmächer, T., Reading, P., & Sonka, K. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01473.x · Cited by 255
Van Cauter, E., Plat, L., Scharf, M. B., Leproult, R., Cespedes, S., L'Hermite-Balériaux, M., & Copinschi, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119587 · Cited by 234
“These dosages are used commonly in the treatment of narcolepsy (17, 18).”
BackgroundSelf-citationCorkery, J. M., Loi, B., Claridge, H., Goodair, C., Corazza, O., Elliott, S., & Schifano, F. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.012 · Cited by 98
Gamma hydroxybutyric acid (ghb) for the treatment of alcohol dependence: A review
Caputo, F., Vignoli, T., Maremmani, I., Bernardi, M., & Zoli, G. (2009) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph6061917 · Cited by 73
“of narcolepsy [12-15].”
Neuroscience-driven discovery and development of sleep therapeutics
Dresler, M., Spoormaker, V. I., Beitinger, P., Czisch, M., Kimura, M., Steiger, A., & Holsboer, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.012 · Cited by 63
Catathrenia under sodium oxybate in narcolepsy with cataplexy
Poli, F., Ricotta, L., Vandi, S., Franceschini, C., Pizza, F., Palaia, V., Moghadam, K. K., Banal, D., Vetrugno, R., Thorpy, M. J., et al. (2012) · Sleep and Breathing · doi:10.1007/s11325-011-0520-2 · Cited by 34
“A large study in NC patients under SO did not report worsening in breathing patterns after 9 years of follow-up [4]; no worsening was reported in a patient with NC and central apneas [17], while an improvement was documented in a patient with concomitant NC and OSA complying with nCPAP [32].”
Background
Metadata
- Authors
- Mamelak, M., Scharf, M. B., & Woods, M.
- Venue
- Sleep
- Publisher
- Oxford University Press (OUP)
- Published
- 1986-03
- Volume
- 9
- Issue
- 1
- Pages
- 285-289
- ISSN
- 0161-8105 (ISSN-L)
- 1550-9109
- OpenAlex
- W44752123
- Cited by
- 231
- References
- 0
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.